Фармакотерапия бронхиальной астмы у беременных: проблемы безопасности


DOI: https://dx.doi.org/10.18565/therapy.2020.2.62-68

Л.З. Болиева, Э.Г. Арчегова

ФГБОУ ВО «Северо-Осетинская государственная медицинская академия» Минздрава России, г. Владикавказ
В статье анализируются результаты клинических исследований, метаанализов, обосновывающие тактику лечения бронхиальной астмы в период беременности. Обсуждаются безопасность применения и критерии выбора лекарственных средств для базисной терапии и лечения обострений этого заболевания у беременных женщин. Показано, что рациональная фармакотерапия бронхиальной астмы служит необходимым условием благополучного исхода беременности у этой категории пациенток.

Литература



  1. Купаев В.И., Косарев В.В., Филиппова Т.Ю. Особенности контроля бронхиальной астмы у женщин в период беременности. Самара: Литфонд. 2004; 103.

  2. Утешев Д.Б., Крылов И.А., Буюклинская О.В. Бронхиальная астма и беременность: тактика ведения. Проблемы женского здоровья. 2007; 2(4): 34–37.

  3. Kwon H.L., Belanger K., Bracken M.B. Asthma prevalence among pregnant and childbearing-aged women in the United States: estimates from national health surveys. Ann Epidemiol. 2003; 13: 317–22.

  4. Tata L.J., Lewis S.A., McKeever Т.М. et al. A comprehensive analysis of adverse obstetric or pediatric complications in women with asthma. Am. J. Respir. Crit. Care Med. 2007; 175: 991–97.

  5. Белан Э.Б., Кляусов А.С. Бронхиальная астма и беременность. Лекарственный вестник. 2014; 8(1): 8–17.

  6. Murphy V.E., Gibson P.G., Smith R., Clifton V.L. Asthma during pregnancy: mechanisms and treatment implications. Eur Respir J. 2005; 25: 731–35.

  7. Schatz M., Dombrowski M.P. Clinical practice. Asthma in pregnancy. N Engl J Med. 2009; 360(18): 1862–69. doi: 10.1056/NEJMcp0809942.

  8. Бронхиальная астма. Клинические рекомендации. Российское респираторное общество. 2019; 97.

  9. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Available at: www.ginasthma.org (reference date – 24.03.2020).

  10. Namazy J.A., Schatz M. Update in the treatment of asthma during pregnancy. Clin Rev Allergy Immunol. 2004; 26: 139–48.

  11. Tamasi L., Horvath I., Bohacs A. et al. Asthma in pregnancy – immunological changes and clinical management. Respir Med. 2011; 105: 159–64. doi: 10.1016/j.rmed.2010.11.006.

  12. Ушкалова Е.А., Ткачева О.Н., Чухарева Н.А. Проблемы безопасности применения лекарственных средств во время беременности и кормления грудью. Акушерство и гинекология. 2011; 2: 4–7.

  13. National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program Asthma and Pregnancy Working Group. NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment – 2004 update. J Allergy Clin Immunol. 2005; 115: 34.

  14. Dombrowski M.P., Schatz M. ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy. Obstet Gynecol. 2008; 111: 457.

  15. Skuladottir H., Wilcox A.J., Ma C. et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res A Clin Mol Teratol. 2014; 100(6): 499–506. doi: 10.1002/bdra.23248.

  16. Schatz M., Dombrowski M.P., Wise R. et al. The relationship of asthma medication use to perinatal outcomes. J Allergy Clin Immunol. 2004; 113: 1040–44.

  17. Bracken M.B., Triche E.W., Belanger K. et al. Asthma symptoms, severity, and drug therapy: a prospective study of effects on 2205 pregnancies. Obstet Gynecol. 2003; 102: 739–44.

  18. Bakhireva L.N., Jones K.L., Schatz M. et al. Asthma medication use in pregnancy and fetal growth. J Allergy Clin Immunol. 2005; 116: 503–09.

  19. Namazy J.A., Murphy V.E., Powell H. et al. Effects of asthma severity, exacerbations and oral corticosteroids on perinatal outcomes. Eur Respir J. 2013; 41: 1082–90. doi: 10.1183/09031936.00195111.

  20. Schatz M. The efficacy and safety of asthma medications during pregnancy. Semin Perinatol. 2001; 25: 145–52.

  21. Stenius-Aarniala B., Piirila P., Teramo K. Asthma and pregnancy: a prospective study of 198 pregnancies. Thorax. 1988; 43: 12–18.

  22. Perlow J.H., Montgomery D., Morgan M.A. et al. Severity of asthma and perinatal outcome. Am J Obstet Gynecol. 1992; 167: 963–67.

  23. Garne E., Vinkel Hansen A., Morris J. et al. Risk of congenital anomalies after exposure to asthma medication in the first trimester of pregnancy – a cohort linkage study. BJOG. 2016; 123: 1609–18.

  24. Kallen B., Rydhstroem H., Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol. 1999; 93: 392–98.

  25. Norjavaara E., de Verdier M.G. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. J Allergy Clin Immunol. 2003; 111: 736–42.

  26. Charlton R.A., Snowball J.M., Nightingale A.L., Davis K.J. Safety of fluticasone propionate prescribed for asthma during pregnancy: a UK population-based cohort study. J Allergy Clin Immunol Pract. 2015; 3: 772–79. doi: 10.1016/j.jaip.2015.05.008.

  27. Cossette B., Beauchesne M.F., Forget A. et al. Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy. Ann Allergy Asthma Immunol. 2014; 112: 459–64. doi: 10.1016/j.anai.2014.02.010.

  28. Blais L., Beauchesne M.F., Lemiere C., Elftouh N. High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations. J Allergy Clin Immunol. 2009; 124: 1229–34. doi: 10.1016/j.jaci.2009.09.025.

  29. Wendel P.J., Ramin S.M., Barnett-Hamm C. et al. Asthma treatment in pregnancy: a randomized controlled study. Am J Obstet Gynecol. 1996; 175: 150–54.

  30. Dombrowski M.P., Schatz M., Wise R. et al. Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy. Am J Obstet Gynecol. 2004; 190: 737–44.

  31. Лаврова О.В., Дымарская Ю.Р. Бронхиальная астма и беременность. Практическая пульмонология. 2015; 4: 2–9.

  32. Luskin A.T., Bukstein D., Ben-Joseph R. The relationship between prescribed and delivered doses of inhaled corticosteroids in adult asthmatics. J Asthma. 2001; 38(8): 645–55.

  33. Enriquez R., Wu P., Griffin M.R. et al. Cessation of asthma medication in early pregnancy. Am J Obstet Gynecol. 2006; 195(1): 149–53.

  34. Schatz M., Leibman C. Inhaled corticosteroid use and outcomes in pregnancy. Ann Allergy Asthma Immunol. 2005; 95(3): 234–38.

  35. Garne E., Hansen A.V., Morris J. et al. Use of asthma medication during pregnancy and risk of specific congenital anomalies: a European case-malformed control study. J Allergy Clin Immunol 2015; 136: 1496–502. doi: 10.1016/j.jaci.2015.05.043.

  36. Cossette B., Beauchesne M.F., Forget A. et al. Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy. Ann Allergy Asthma Immunol. 2014; 112(5): 459–64. doi: 10.1016/j.anai.2014.02.010.

  37. Wilton L.V., Shakir S.A. A post-marketing surveillance study of formoterol (Foradil): its use in general practice in England. Drug Saf. 2002; 25: 213–23.

  38. The use of newer asthma and allergy medications during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI). Ann Allergy Asthma Immunol. 2000; 84: 475.

  39. Лаврова О., Дымарская Ю., Петрова М. Влияние характера течения и лечения бронхиальной астмы на развитие осложнений беременности и родов. Врач. 2015; 7: 52–55.

  40. Eltonsy S., Forget A., Beauchesne M.F., Blais L. Risk of congenital malformations for asthmatic pregnant women using a long-acting β₂-agonist and inhaled corticosteroid combination versus higher-dose inhaled corticosteroid monotherapy. J Allergy Clin Immunol. 2015; 135:123–30. doi: 10.1016/j.jaci.2014.07.051.

  41. Bakhireva L.N., Jones K.L., Schatz M. et al. Safety of leukotriene receptor antagonists in pregnancy. J Allergy Clin Immunol. 2007; 119: 618–25.

  42. Sarkar M., Koren G., Kalra S. et al. Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes. Eur J Clin Pharmacol. 2009; 65: 1259–64. doi: 10.1007/s00228-009-0713-9.

  43. Nelsen L.M., Shields K.E., Cunningham M.L. et al. Congenital malformations among infants born to women receiving montelukast, inhaled corticosteroids, and other asthma medications. J Allergy Clin Immunol. 2012; 129: 251–54. doi: 10.1016/j.jaci.2011.09.003.

  44. Bain E., Pierides K.L., Clifton V.L. et al. Interventions for managing asthma in pregnancy. Cochrane Database Syst Rev. 2014; CD010660. doi: 10.1002/14651858.

  45. Namazy J.A., Blais L., Andrews E.B. et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol. 2020; 145: 528–36. doi: 10.1016/j.jaci.2019.05.019.

  46. Инструкции по медицинскому применению препаратов, содержащих МНН меполизумаб, реслизумаб, бенрализумаб, дупилумаб. Режим доступа: https://grls.rosminzdrav.ru/grls.aspx (дата обращения – 24.03.2020).

  47. Аллергология и иммунология: национальное руководство. Под ред. Р.М. Хаитова, Н.И. Ильиной. М.: ГЭОТАР-Медиа. 2009; 656 с.

  48. Schatz M., Wise R.A. Acute asthma in pregnancy. In: Acute Asthma: Assessment and Management, Corbridge T. et al (Eds), McGraw-Hill, New York 2000.

  49. Cates C.J., Welsh E.J., Rowe B.H. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2013; 9: CD000052. doi: 10.1002/14651858.

  50. Rodrigo G.J., Rodrigo C., Hall J.B. Acute asthma in adults: a review. Chest. 2004; 125: 1081–102.

  51. Hasegawa T., Ishihara K., Takakura S. et al. Duration of systemic corticosteroids in the treatment of asthma exacerbation; a randomized study. Intern Med. 2000; 39: 794–97.

  52. Jones A.M., Munavvar M., Vail A. et al. Prospective, placebo-controlled trial of 5 vs 10 days of oral prednisolone in acute adult asthma. Respir Med. 2002; 96: 950–54.

  53. Rodrigo G.J., Castro-Rodriguez J.A. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax. 2005; 60: 740–46.

  54. Camargo C.A. Jr, Spooner C.H., Rowe B.H. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev. 2003; 4: CD001115.

  55. Kolbe J., Fergusson W., Garrett J. Rapid onset asthma: a severe but uncommon manifestation. Thorax. 1998; 53: 241–47.

  56. Rowe B.H., Bretzlaff J.A., Bourdon C. et al. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database Syst Rev. 2000; 2: CD001490.

  57. FitzGerald J.M. Magnesium sulfate is effective for severe acute asthma treated in the emergency department. West J Med. 2000; 172: 96.

  58. Wendel P.J., Ramin S.M., Barnett-Hamm C. et al. Asthma treatment in pregnancy: a randomized controlled study. Am J Obstet Gynecol. 1996; 175: 150–54.


Об авторах / Для корреспонденции


Лаура Зелимхановна Болиева, д.м.н., профессор, зав. кафедрой фармакологии с клинической фармакологией ФГБОУ ВО «Северо-Осетинская государственная медицинская академия» Минздрава России.
Адрес: 362019, г. Владикавказ, ул. Пушкинская, д. 40. Тел.: 8 (8672) 28-08-92. E-mail: bolievalz@mail.ru
Элла Георгиевна Арчегова, ассистент кафедры фармакологии с клинической фармакологией ФГБОУ ВО «Северо-Осетинская государственная медицинская академия» Минздрава России. Адрес: 362019, г. Владикавказ,
ул. Пушкинская, д. 40. Тел.: 8 (8672) 28-08-92|


Похожие статьи


Бионика Медиа